cancer patient News
-
Circulating atypical cells detected in blood of lung cancer patients
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...
By X-Zell Inc.
-
T3 Pharma closes first financing round to advance research and preclinical development of breakthrough bacteria-based cancer therapies
T3 Pharmaceuticals Ltd (“T3 Pharma”), a Swiss-based biotechnology company specializing in breakthrough bacteria–based cancer therapies, today announced the successful closing of its first financing round. The funding has been provided by private Swiss investors and will secure further growth of the company, in particular the expansion of research activities and the initiation ...
-
2nd PhD student appointed to the Toxicity Atlas project
We are very happy to welcome Ghislaine Deutsch as the second PhD student working on the Toxicity Atlas! In the Toxicity Atlas project, Medstoner Silvia Scoarta, VUmc professor Bart Westerman, and their team are researching better ways to treat brain cancer. Quite the task! Ghislaine’s expertise in biology and bio-informatics will make a great contribution to the project by, among other ...
-
Radiotherapy That Could Halve Prostate Cancer Treatment Time Recommended For Use in Wales
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy is included as part of primary treatment in approximately 30% of ...
By MediWales
-
Toxicity Atlas presentation CCA Conference
Last Friday, Medstoner Silvia presented the main findings of her first manuscript at the 5th Cancer Center Amsterdam (CCA) Conference! The manuscript entitled “A roadmap to use non-structured data to discover multi-target cancer vulnerabilities” highlights the lack of consistency in the currently available public data and discusses the importance of extracting information from ...
-
Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients
Results from an investigator-initiated phase II study performed by researchers at Rigshospitalet and using the uTRACE[®] technology have now been published online ahead of print in the prestigious Journal of Nuclear Medicine. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/34857658/). The phase II study The phase II trial (NCT02965001) aimed to ...
By Curasight
-
Precision therapeutics continues dedicated support to the NOCC `walk to break the silence`
Precision Therapeutics will sponsor the Pittsburgh Chapter of the National Ovarian Cancer Coalition's "Walk to Break the Silence" on Sunday, September 12, 2010. The walk, which takes place at the North Park Boathouse, is an optional 1 or 5 mile hike to benefit ovarian cancer awareness. Hoping that a great number of its employees will unite to help fortify the partnerships it has forged in ...
-
Cleaning for the right reason
Cleaning for a Reason Offers Housecleaning Services At No Cost to Cancer Patients - 667 partners in 50 states National Cleaning for Reason Week Held April 18-24, 2010 SDA Members Raise $10,000+ at First-Ever Charity Golf Tournament For a number of Americans, cleaning the house is about more than just have a tidy home. It's helping to keep their homes clean when their immune systems are ...
-
Betaglue technologies strengthen its expertise in strategic areas with four new managers
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Caia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas Clinical developments continue on the advanced cancer radiotherapy platform, BAT-90, as the first breast cancer patient was treated Milan, October 19, 2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, ...
-
xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting
Today, xCures announced that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of November 2022, in Tampa Bay, Florida. The Society for Neuro-Oncology is a multidisciplinary society of healthcare professionals dedicated to promoting advances in neuro-oncology through research and education. Their annual meeting features research ...
By xCures
-
Precision Diagnostic of Cancer Therapies with Dr. Chorom Pak LynxBio
Dr. Chorom Pak, President and CEO, LynxBio was a finalist in the John G. Watson Quick Pitch Competition presented by the Tech Coast Angels and the San Diego Venture Group. She talks about using an advanced approach to diagnosing cancer by using a standard-of-care biopsy to create a living model of a patient's cancer, including the patient's own microenvironment, to rapidly identify effective ...
-
BetaGlue strengthen its expertise in strategic areas with four new managers
Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni strengthen the Clinical Research, Manufacturing and Quality areas BetaGlue Technologies has appointed four new managers, strengthening the team across strategic fields for its business development: Betty Polikar, Gianluca De Danieli, Pietro Bubba Bello and Gaia Bisaccioni joined the company in September in the ...
-
Showcase
RTsafe’s core role for the development of German guidelines for a standard, safe and efficient implementation of Single-Isocentric Multi-Focal SRS throughout the country
RTsafe is happy to announce that its PRIME and Pseudopatient 3D phantoms, have been selected by a consortium of high-end German Radiotherapy Institutions – led by the Division of Medical Physics of the Department of Radiation Oncology at the Medical Center of University of Freiburg – towards supporting a study whose results will be used for the development of national guidelines in ...
By RTsafe
-
New Bone Data Comparing ImpediMed’s SOZO to DXA in Cancer Patients to be Presented at 39th Annual Miami Breast Cancer Conference
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce an abstract comparing concurrent measures using ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing in bone mineral content in cancer patients was accepted for ...
-
Filtricine Preclinical Results Published
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology, Targeted Nutrients Deprivation (TND), have been published in Nutrition and Cancer. “Broad Anti-Cancer Activity Produced by Targeted Nutrients Deprivation (TND) of Multiple Non-Essential Amino Acids” Filtricine’s core medical food technology is the ...
-
SeqOne Genomics selected as genomic analysis solution for CELIA (Comprehensive Genomic profiling impact) project, in collaboration with Illumina
The project aims to compare the clinical utility of broad-spectrum genomic profiling in the treatment of late-stage cancer patients with more traditional approaches that analyze a limited set of genes and thus influence the precision medicine strategy of the French national health system SeqOne Genomics, developer of next generation genomic analysis solutions, announced that it has been selected ...
-
xCures and mProbe partner to help cancer patients determine optimal treatments
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and its treatments advance, it is ever ...
By xCures
-
Pancreatic Cancer Patients Will Now Have Remote Access to Precision Nutrition Trial Through New Partnership
xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. The ...
By xCures
-
Now recruiting: Bioinformatics Scientist
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
-
Building comprehensive breast cancer care eco-system for the wellness of cancer patients and their families by joint efforts of Beijing Love Book Cancer Foundation (LBCF) and Aurora
Beijing Love Book Cancer Foundation and Aurora Healthcare US Corp are pleased to announce their partnership to build a comprehensive breast cancer care eco-system for the wellness of women, breast cancer patients and their families. High morbidity and mortality of breast cancer in China have become one of the major healthcare and social problems, with more than 360,000 newly diagnosed cases ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you